<DOC>
	<DOC>NCT01719380</DOC>
	<brief_summary>This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer</brief_summary>
	<brief_title>Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Metastatic colorectal cancer Progression after at least one prior standard of care regimen or be intolerant to irinotecanbased regimens Life expectancy ≥ 3 months ECOG performance status ≤ 2 Symptomatic or untreated leptomeningeal disease Symptomatic brain metastasis Patients with clinically manifested diabetes Acute or chronic pancreatitis Clinically significant cardiac disease Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Open-label dose escalation; BRAF inhibitor; LGX818; PI3K inhibitor; BYL719; EGFR; cetuximab; metastatic colorectal cancer; KRAS; BRAF; V600</keyword>
</DOC>